*** TEST ***
Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

The polyphenol EGCG directly targets intracellular amyloid-β aggregates and promotes their lysosomal degradation

[thumbnail of Original Article]
Preview
PDF (Original Article) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
4MB
[thumbnail of Supplementary Material]
Preview
PDF (Supplementary Material) - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
5MB

Item Type:Article
Title:The polyphenol EGCG directly targets intracellular amyloid-β aggregates and promotes their lysosomal degradation
Creators Name:Secker, C., Motzny, A.Y., Kostova, S., Buntru, A., Helmecke, L., Reus, L., Steinfort, R., Brusendorf, L., Boddrich, A., Neuendorf, N., Diez, L., Schmieder, P., Schulz, A., Czekelius, C. and Wanker, E.E.
Abstract:The accumulation of amyloidogenic protein aggregates in neurons is a pathogenic hallmark of a large number of neurodegenerative diseases including Alzheimer's disease (AD). Small molecules targeting such structures and promoting their degradation may have therapeutic potential for the treatment of AD. Here, we searched for natural chemical compounds that decrease the abundance of stable, proteotoxic β-sheet-rich amyloid-β (Aβ) aggregates in cells. We found that the polyphenol (-)-epigallocatechin gallate (EGCG) functions as a potent chemical aggregate degrader (CAD) in SH-EP cells. We further demonstrate that a novel, fluorescently labeled EGCG derivative (EGC-dihydroxybenzoate (DHB)-Rhodamine) also shows cellular activity. It directly targets intracellular Aβ42 aggregates and competes with EGCG for Aβ42 aggregate binding in vitro. Mechanistic investigations indicated a lysosomal accumulation of Aβ42 aggregates in SH-EP cells and showed that lysosomal cathepsin activity is critical for efficient EGCG-mediated aggregate clearance. In fact, EGCG treatment leads to an increased abundance of active cathepsin B isoforms and increased enzymatic activity in our SH-EP cell model. Our findings suggest that intracellular Aβ42 aggregates are cleared through the endo-lysosomal system. We show that EGCG directly targets intracellular Aβ42 aggregates and facilitates their lysosomal degradation. Small molecules, which bind to protein aggregates and increase their lysosomal degradation could have therapeutic potential for the treatment of amyloid diseases.
Keywords:Alzheimer’s Disease, Amyloid-ß, EGCG, Lysosome, Cathepsin, EGCG Derivatives
Source:Journal of Neurochemistry
ISSN:0022-3042
Publisher:Wiley
Volume:166
Number:2
Page Range:294-317
Date:18 July 2023
Official Publication:https://doi.org/10.1111/jnc.15842
PubMed:View item in PubMed

Repository Staff Only: item control page

Downloads

Downloads per month over past year

Open Access
MDC Library